Apixaban for acute calf blood clots
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether apixaban (an anticoagulant/blood thinner) works safely and effectively for people with a new blood clot in the calf. It aims to prevent the clot from worsening or causing complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- Your calf clot symptoms started less than 10 days ago
- Your clot is confirmed by leg ultrasound as a calf (distal) deep vein clot
- You do not have a clot in the higher (proximal) leg veins
- You are not pregnant or breast-feeding
- You can give informed consent and are not in another trial now or in the last 30 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the blood thinner apixaban is safe and effective for cancer patients who have low platelets and a recent blood clot. It may offer a treatment option for those who cannot take standard blood thinners.
This trial studies a procedure to remove an acute deep vein blood clot in the leg. It may help restore blood flow faster than standard treatment for certain clot locations.
This study tests whether a lower dose of the blood thinner apixaban (Eliquis) can safely prevent another blood clot in people with cancer who have a catheter-related clot in their upper arm or neck. It aims to find a balance between preventing clots and reducing bleeding risk.
This trial tests whether a medication called apixaban (a blood thinner) can safely prevent blood clots after abdominal or pelvic surgery. It is for people who have a moderate risk of clots and bleeding, and who are not taking other blood thinners.
This trial tests whether the blood thinner apixaban can prevent dangerous blood clots from forming in the heart's main pumping chamber after a specific type of heart attack. It is for patients who have severe weakness of the left ventricle and no clot already present.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
Hear when a new Deep Vein Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.